Aigen Investment Management LP Takes $286,000 Position in Natera, Inc. (NASDAQ:NTRA)

Aigen Investment Management LP purchased a new stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 1,805 shares of the medical research company's stock, valued at approximately $286,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Proficio Capital Partners LLC purchased a new stake in Natera in the fourth quarter worth about $16,113,000. M&T Bank Corp raised its holdings in Natera by 27.6% in the 4th quarter. M&T Bank Corp now owns 7,033 shares of the medical research company's stock worth $1,113,000 after acquiring an additional 1,520 shares during the last quarter. Assetmark Inc. lifted its holdings in shares of Natera by 51.7% during the fourth quarter. Assetmark Inc. now owns 11,154 shares of the medical research company's stock valued at $1,766,000 after purchasing an additional 3,801 shares in the last quarter. Victory Capital Management Inc. lifted its stake in Natera by 11.0% during the 4th quarter. Victory Capital Management Inc. now owns 350,201 shares of the medical research company's stock valued at $55,437,000 after acquiring an additional 34,658 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Natera by 8.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 867,496 shares of the medical research company's stock worth $137,325,000 after purchasing an additional 64,962 shares during the last quarter. Institutional investors own 99.90% of the company's stock.

Analyst Ratings Changes

Several research firms have recently commented on NTRA. JPMorgan Chase & Co. upped their price target on shares of Natera from $160.00 to $200.00 and gave the company an "overweight" rating in a research report on Friday, December 13th. Guggenheim boosted their target price on shares of Natera from $170.00 to $200.00 and gave the stock a "buy" rating in a report on Friday, January 17th. The Goldman Sachs Group increased their price target on Natera from $160.00 to $190.00 and gave the company a "buy" rating in a research note on Tuesday, January 28th. StockNews.com upgraded shares of Natera from a "sell" rating to a "hold" rating in a report on Tuesday. Finally, Craig Hallum increased their price target on Natera from $121.00 to $157.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $173.56.

Remove Ads

Natera Stock Performance

Shares of Natera stock traded up $4.48 on Wednesday, reaching $144.50. 2,549,996 shares of the stock were exchanged, compared to its average volume of 1,761,105. The business has a 50 day moving average price of $164.73 and a two-hundred day moving average price of $148.28. The firm has a market capitalization of $19.53 billion, a price-to-earnings ratio of -82.10 and a beta of 1.80. Natera, Inc. has a twelve month low of $83.13 and a twelve month high of $183.00. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.01. The business had revenue of $476.10 million during the quarter, compared to analysts' expectations of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. Analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Buying and Selling at Natera

In other Natera news, CEO Steven Leonard Chapman sold 87,272 shares of the company's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $143.40, for a total value of $12,514,804.80. Following the completion of the transaction, the chief executive officer now owns 203,354 shares in the company, valued at approximately $29,160,963.60. This represents a 30.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider John Fesko sold 669 shares of the stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $159.60, for a total value of $106,772.40. Following the transaction, the insider now owns 114,142 shares in the company, valued at $18,217,063.20. This represents a 0.58 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 294,946 shares of company stock worth $47,212,702. Insiders own 7.60% of the company's stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.